James Gulley, MD, Oncology, Bethesda, MD, National Institutes of Health Clinical Center

JamesLGulleyMDPh.D.

Oncology Bethesda, MD

Genitourinary Oncology, Hematologic Oncology

Clinical Trials Group Center for Cancer Research National Cancer Institute

Dr. Gulley is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gulley's full profile

Already have an account?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1998 - 2001
  • Emory University
    Emory UniversityResidency, Internal Medicine, 1995 - 1998
  • Loma Linda University School of Medicine
    Loma Linda University School of MedicineClass of 1995

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2001 - 2022
  • GA State Medical License
    GA State Medical License 1996 - 2007
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2008-2013
  • Top Doctors:Baltimore Area Castle Connolly, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Vaccines as an Integral Component of Cancer Immunotherapy  
    James Gulley, MD, JAMA Psychiatry

Abstracts/Posters

  • Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies
    James Gulley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatec... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • New Agents in Clinical Trials: Significant Phase I-III Clinical Trials. The Future of Immunotherapy: Novel Agents in Clinical Trials 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Press Mentions

  • JAVELIN Solid Tumor Clinical Trials Evaluating Use of Avelumab
    JAVELIN Solid Tumor Clinical Trials Evaluating Use of AvelumabOctober 24, 2020 18:56
  • Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-Associated Cancers
    Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-Associated CancersAugust 18, 2020 10:50
  • AUA 2020: Why Precision Matters: Implications of Genomic Analysis for mCRPC
    AUA 2020: Why Precision Matters: Implications of Genomic Analysis for mCRPCJune 28, 2020 10:33
  • Join now to see all

Grant Support

  • Clinical Trials Employing Cancer Vaccine Combination TherapiesNational Cancer Institute2010–2011
  • Cancer Therapy Clinical Trials Using Novel Recombinant VaccinesNational Cancer Institute2010–2011
  • Clinical Trials Employing Cancer Vaccine Combination TherapiesDivision Of Basic Sciences - Nci2009
  • Cancer Therapy Clinical Trials Using Novel Recombinant VaccinesDivision Of Basic Sciences - Nci2009
  • Clinical Trials Employing Cancer Vaccine Combination TherapiesNational Cancer Institute2008
  • Cancer Therapy Clinical Trials Using Novel Recombinant VaccinesNational Cancer Institute2008
  • Vaccine Clinical TrialsNational Cancer Institute2007
  • Vaccine Clinical TrialsDivision Of Basic Sciences - Nci2005–2006

Professional Memberships

Hospital Affiliations